Skip to main content

Table 3 (A) Treatment-emergent non-hematologic adverse events occurring in greater than 10% of patients and (B) Grade 3–4 hematologic abnormalities (N = 46)

From: A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors

(A)

 

Severity grade, n (%)

Preferred term

1

2

3

4

Overall (N = 46)

Fatigue

9 (20)

8 (17)

2 (4)

0

19 (41)

Headache

14 (30)

2 (4)

0

0

16 (35)

Chills

11 (24)

3 (7)

1 (2)

0

15 (33)

Pyrexia

8 (17)

4 (9)

0

0

12 (26)

Nausea

8 (17)

2 (4)

1 (2)

0

11 (24)

Diarrhoea

8 (17)

1 (2)

0

0

9 (20)

Dyspnoea

4 (9)

5 (11)

0

0

9 (20)

Cough

7 (15)

0

0

0

7 (15)

Back pain

3 (7)

2 (4)

1 (2)

0

6 (13)

Depression

4 (9)

2 (4)

0

0

6 (13)

Musculoskeletal pain

4 (9)

2 (4)

0

0

6 (13)

Abdominal pain

1 (2)

2 (4)

2 (4)

0

5 (11)

Asthenia

2 (4)

2 (4)

1 (2)

0

5 (11)

Constipation

5 (11)

0

0

0

5 (11)

Oedema peripheral

4 (9)

1 (2)

0

0

5 (11)

Oropharyngeal pain

5 (11)

0

0

0

5 (11)

Vomiting

2 (4)

2 (4)

1 (2)

0

5 (11)

(B)

 

Grade 3

Grade 4

 

n (%)

n (%)

Lymphopenia

14 (30)

5 (11)

Neutropenia

5 (11)

1 (2)

Thrombocytopenia

7 (15)

2 (4)

Leukopenia

6 (13)

1 (2)